Hypertension Management Guidelines

Introduction to Antihypertensive Therapies

The European Society of Cardiology recommends specific combinations of antihypertensive medications, but does not include spironolactone in first-line combination therapies, instead positioning it as a fourth-line agent for resistant hypertension 1, 2
Beta-blockers are primarily indicated for specific conditions (angina, post-MI, heart failure) rather than first-line hypertension treatment, according to the European Society of Cardiology and American College of Cardiology 3, 4, 5

Spironolactone is primarily used as an add-on therapy for heart failure with reduced ejection fraction and resistant hypertension, added when triple therapy (RAS blocker, CCB, and thiazide diuretic) fails to control blood pressure 1, 2, 6
The American College of Cardiology highlights concerns with spironolactone, including the potential to cause significant hypotension, especially when combined with ACE inhibitors, and limited evidence for benefit in HFmrEF specifically 7

There is a risk of hyperkalemia when combining spironolactone with RAS blockers, and monitoring of renal function and electrolytes (particularly potassium) is recommended 6, 5
Monitor for signs of hypotension, especially in elderly patients, and adjust medications accordingly, considering reducing diuretic dose or temporarily discontinuing one of the medications if symptomatic hypotension is confirmed 6, 8

Elderly patients (>80 years) require special attention due to increased sensitivity to volume depletion and higher risk of falls and injury from hypotension, according to the American College of Cardiology and American Heart Association 8
Consider patient's overall heart failure status and monitor for hyperkalemia when using the combination of lisinopril and spironolactone, especially in elderly patients with potential renal impairment 5
Do not stop beta-blockers abruptly if the patient is on them, as this carries a risk of rebound ischemia, according to the American College of Cardiology 5

Consider halving the dose of lisinopril (to 10mg) or reducing spironolactone to 12.5mg daily if falls continue despite initial adjustments in patients with HFmrEF 6
Reassess symptoms and blood pressure within 1-2 weeks and adjust medications based on clinical response in patients with HFmrEF 6